Immunome Financial Statements (IMNM)
|
|
|
|
Report date
|
|
|
09.11.2023 |
28.03.2024 |
14.05.2024 |
12.08.2024 |
13.11.2024 |
|
13.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
3.57 |
3.83 |
1.03 |
2.36 |
2.91 |
|
10.1 |
|
Operating Income, bln rub |
|
|
-4.63 |
-94.7 |
-132.3 |
-40.0 |
-50.5 |
|
-317.5 |
|
EBITDA, bln rub |
? |
|
-4.52 |
-13.7 |
-20.2 |
-35.4 |
-50.5 |
|
-119.9 |
|
Net profit, bln rub |
? |
|
-4.35 |
-92.6 |
-129.5 |
-36.1 |
-47.1 |
|
-305.3 |
|
|
OCF, bln rub |
? |
|
-8.61 |
-17.5 |
-11.2 |
-23.4 |
-34.2 |
|
-86.2 |
|
CAPEX, bln rub |
? |
|
0.036 |
0.349 |
2.16 |
2.34 |
1.54 |
|
6.40 |
|
FCF, bln rub |
? |
|
-8.65 |
-17.8 |
-13.3 |
-25.7 |
-35.7 |
|
-92.6 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
8.20 |
98.2 |
133.1 |
41.7 |
53.4 |
|
326.4 |
|
Cost of production, bln rub |
|
|
0.166 |
0.257 |
0.263 |
0.673 |
0.000 |
|
1.19 |
|
R&D, bln rub |
|
|
3.82 |
90.2 |
127.1 |
29.1 |
6.71 |
|
253.0 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.201 |
0.000 |
0.000 |
0.000 |
|
0.201 |
|
|
Assets, bln rub |
|
|
93.2 |
148.5 |
319.8 |
296.2 |
256.9 |
|
256.9 |
|
Net Assets, bln rub |
? |
|
6.08 |
119.9 |
285.6 |
253.8 |
214.9 |
|
214.9 |
|
Debt, bln rub |
|
|
0.371 |
1.65 |
1.63 |
2.77 |
2.46 |
|
2.46 |
|
Cash, bln rub |
|
|
90.6 |
138.1 |
309.7 |
278.4 |
240.1 |
|
240.1 |
|
Net debt, bln rub |
|
|
-90.3 |
-136.5 |
-308.1 |
-275.6 |
-237.7 |
|
-237.7 |
|
|
Ordinary share price, rub |
|
|
8.35 |
10.7 |
24.7 |
12.1 |
14.6 |
|
2.50 |
|
Number of ordinary shares, mln |
|
|
12.2 |
22.0 |
10.3 |
59.9 |
60.2 |
|
60.2 |
|
|
Market cap, bln rub |
|
|
102 |
235 |
254 |
725 |
880 |
|
151 |
|
EV, bln rub |
? |
|
12 |
98 |
-54 |
450 |
643 |
|
-87 |
|
Book value, bln rub |
|
|
6 |
120 |
286 |
254 |
215 |
|
215 |
|
|
EPS, rub |
? |
|
-0.36 |
-4.22 |
-12.6 |
-0.60 |
-0.78 |
|
-5.07 |
|
FCF/share, rub |
|
|
-0.71 |
-0.81 |
-1.29 |
-0.43 |
-0.59 |
|
-1.54 |
|
BV/share, rub |
|
|
0.50 |
5.46 |
27.7 |
4.24 |
3.57 |
|
3.57 |
|
|
EBITDA margin, % |
? |
|
-126.8% |
-358.1% |
-1 962% |
-1 500% |
-1 736% |
|
-1 183% |
|
Net margin, % |
? |
|
-121.9% |
-2 421% |
-12 584% |
-1 528% |
-1 619% |
|
-3 015% |
|
FCF yield, % |
? |
|
2.60% |
-3.58% |
-18.0% |
-9.04% |
-10.5% |
|
-61.5% |
|
ROE, % |
? |
|
-368.3% |
-88.9% |
-81.3% |
-103.4% |
-142.1% |
|
-142.1% |
|
ROA, % |
? |
|
-24.0% |
-71.8% |
-72.6% |
-88.6% |
-118.9% |
|
-118.9% |
|
|
P/E |
? |
|
-4.55 |
-2.20 |
-1.10 |
-2.76 |
-2.88 |
|
-0.49 |
|
P/FCF |
|
|
38.4 |
-28.0 |
-5.56 |
-11.1 |
-9.51 |
|
-1.63 |
|
P/S |
? |
|
10.00 |
16.8 |
20.1 |
67.3 |
86.9 |
|
14.9 |
|
P/BV |
? |
|
16.8 |
1.96 |
0.89 |
2.86 |
4.10 |
|
0.70 |
|
EV/EBITDA |
? |
|
-0.52 |
-3.48 |
1.22 |
-6.09 |
-5.36 |
|
0.73 |
|
Debt/EBITDA |
|
|
4.08 |
4.82 |
7.00 |
3.73 |
1.98 |
|
1.98 |
|
|
R&D/CAPEX, % |
|
|
10 619% |
25 840% |
5 872% |
1 241% |
435.7% |
|
3 956% |
|
|
CAPEX/Revenue, % |
|
|
1.01% |
9.12% |
210.3% |
99.2% |
52.9% |
|
63.1% |
|
| Immunome shareholders |
